FMC benefits from figures and pulls Fresenius to the top of the Dax

In response, to the results from Fresenius Medical Care ( FMC ) the companys shares saw a significant increase in value on Tuesday. By noon the stock price had risen by 2. 1 Percent to 37. 31 Euros, marking a continued recovery from its point in early September. Despite this trend the overall performance of the stock this year remains in the territory down, by 2 percent.

Following the growth of FMCs performance, on the market scene lately has resulted in an increase of 2% in Freseniuts shares to 33€89 cents, per share. This notable rise solidified their position at the forefront of the stock index. Indicates a gain exceeding 20% since the start of this year. FMC was separated from the healthcare conglomerate Freseniuts a year ago; however Freseniuts retains a stake just shy of one third in this dialysis service provider.

The restructuring efforts, at FMC are proving successful as evidenced by the increase in operating profit during the third quarter, which exceeded expectations.The two business divisions saw a growth compared to the year signaling positive developments under the leadership of CEO Helen Giza.Additionally there has been a turnaround in treatment outcomes in the US leading to an outlook for the companys performance, for the rest of the year.

Financial expert Richard Felton, from the known US bank Goldman Sachs commended the numbers from FMC as "impressive". Christian Ehmann, an analyst, at Warburg Research described the quarter positively highlighting the profits achieved through cost saving measures especially in labor expenses.

Analyst James Vane Tempest, from Jefferies noted that the third quarter performed better than anticipated in terms of operating profit and showed results, in adjusted net profit levels. Similarly viewed as positive by David Adlington at JPMorgan is the operating outcome; however he pointed out that the revenue of the dialysis provider fell short of expectations.